Le Lézard
Classified in: Business
Subjects: MAV, CPG, CFG

/R E P E A T -- MEDIA ADVISORY - FEDERAL GOVERNMENT TO MAKE HOUSING ANNOUNCEMENT IN SASKATOON/


SASKATOON, SK, Feb. 27, 2024 /CNW/ - The federal government will make a housing announcement in Saskatoon.

Media are invited to join the Honourable Randy Boissonnault, Member of Parliament for Edmonton Centre, Alberta on behalf of the Honourable Sean Fraser, Minister of Housing, Infrastructure and Communities, and Charlie Clark, Mayor of Saskatoon.

Date:

February 28, 2024



Time:

9:30 am CST



Location: 

Saskatoon City Hall


222 3rd Ave N, Saskatoon, SK 


S7K 0J5
(Inside Committee Room E)

SOURCE Government of Canada


These press releases may also interest you

at 07:22
Tiger Brokers (HK) officially launches virtual asset trading services, leading the way in Hong Kong's online brokerage industry
Tiger Brokers (HK) ("Tiger Brokers (HK)" or "Tiger...

at 07:17
NAPCO Reports Record Revenues, Net Income and Adjusted EBITDA* for Q3 of Fiscal 2024
NAPCO Security Technologies, Inc. , one of the leading manufacturers and designers of high-tech...

at 07:15
Flow Capital Announces Repayment of USD 4.5 Million Investment
Flow Capital Corp. ("Flow Capital"), a leading provider of flexible growth capital solutions, is pleased to announce the full repayment of a USD 4.5 million investment in an environmental solutions provider. Flow Capital continues to focus on...

at 07:10
bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
bluebird bio, Inc. announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET. To participate in the conference call, please dial +1 (800) 715-9871 (U.S. and Canada) and...

at 07:05
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and...

at 07:00
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2024 net product revenue of $21.6 million...

More news about Business...


News published on and distributed by: